JSPR Stock — Jasper Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.62

Market cap

$20.6M

Cash

$7.3M

Enterprise value

$13.3M

Balance sheet

Cash	$7.3M
Debt	$0.0M
Net cash	$7.3M
Enterprise value	$13.3M
Basic shares	28.1M shares
Fully diluted shares	37.2M shares
Fully diluted market cap	$23.1M
Cash per share	$0.26

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading JSPR daily closes…

Loading price history…

Pipeline assets

Briquilimab

Phase 1 · Active Modality: monoclonal antibody (aglycosylated anti-KIT)

Aliases JSP191

Target CD117 (KIT)

Partnerships Stanford: exclusive worldwide license (2021, amended Jun 2026) in hematopoietic cell transplant conditioning field; milestones up to $9.0M + low single-digit royalties. CIRM grant (co-funding; $2.3M liability reversed Q2 2026 after determining no repayment).

Indications

Severe combined immunodeficiency (conditioning for second stem cell transplant) (Phase 1)
Chronic spontaneous urticaria (CSU) (Stage not disclosed)
Chronic inducible urticaria (CIndU) (Stage not disclosed)

Catalysts

— Q1 2027
— H2 2026

Status note Principal path is obtaining and monetizing a priority review voucher (SCID: Orphan + Fast Track + Rare Pediatric Disease designations). 2025 restructuring halted Phase 1b asthma enrollment and discontinued other briquilimab programs; refocusing on SCID and mast cell diseases.

KP-104

Phase 2 · Active Modality: bifunctional biologic

Aliases vensobafusp alfa

Target complement cascade (alternative + terminal pathways)

Indications

IgA nephropathy (IgAN) (Phase 2)
C3 glomerulopathy (C3G) (Phase 2)
Paroxysmal nocturnal hemoglobinuria (treatment-naive) (Phase 2)

Catalysts

— Q4 2026
— Q2 2027
— Q2 2027
— H1 2027
— end of 2026

Status note Acquired via Kira Pharmaceuticals merger (Jul 16, 2026). Phase 2/3-ready; ongoing Phase 2 basket trial in rare renal indications with potential expansion to FSGS. End-of-Phase 2 FDA meeting planned for PNH.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	140,000	no change	0.00%	2026-08-14
Ikarian Capital	24,093	no change	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

JSPR — Jasper Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders